Human T Cell and Antibody-Mediated Responses to the Mycobacterium tuberculosis Recombinant 85A, 85B, and ESAT-6 Antigens

Table 1

Clinical characteristics of TB patients and controls in this study.

Groups	No. of subjects	TST	Males/females	Age (mean ± SD)	Age range
Non-infected (NI)	7	−	05/02	40.1±9.5	28–55
TB patients under treatment (PT)*	25	+	14/11	39.8±14.6	22–76
Pulmonary TB untreated (P)	13	+	09/04	41.0±15.7	19–69
Extra-pulmonary TB (EP)	12	+	08/04	41.1±16.5	21–76
(i)Pleural	6
(ii)Miliary	5
(iii)Intestinal	1

*The treatment consisted of Rifampicin (10–20 mg/kg/day), Isoniazide (10–20 mg/kg/day), and Piraminazide (30–50 mg/kg/day). PT patients were undergoing 1–3 months of chemotherapy. TST tuberculin skin test.